MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-05-2024
Catalent Cost of Revenue 2011-2026 | CTLT
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Catalent
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.43 B | 3.22 B | 3.19 B | 2.65 B | 2.11 B | 1.71 B | 1.71 B | 1.42 B | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.43 B | 1.42 B | 2.43 B |
Quarterly Cost of Revenue Catalent
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 842 M | - | 845 M | 853 M | 813 M | - | 857 M | 762 M | 764 M | 1.53 B | 850 M | 812 M | 701 M | 1.51 B | 687 M | 613 M | 597 M | 613 M | 597 M | 489 M | 487 M | 489 M | 487 M | 422 M | 403 M | 422 M | 403 M | 419 M | 404 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.53 B | 403 M | 691 M |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
5.82 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M | USA |
 |
China Pharma Holdings
CPHI
|
6.51 M | $ 0.57 | -9.62 % | $ 9.95 M |  China |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | - | - | $ 2.06 B |  France |
 |
DURECT Corporation
DRRX
|
1.72 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
705 M | $ 8.01 | -0.5 % | $ 410 M | USA |
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 3.13 | 2.62 % | $ 44 M | USA |
 |
Pacira BioSciences
PCRX
|
170 M | $ 23.2 | 2.43 % | $ 1.07 B | USA |
 |
Harrow Health
HROW
|
67.9 M | $ 35.2 | 3.53 % | $ 1.29 B | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
8.63 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Perrigo Company plc
PRGO
|
2.76 B | $ 9.64 | 0.73 % | $ 1.34 B | USA |
 |
ProPhase Labs
PRPH
|
52 M | - | - | $ 5.07 M | USA |
 |
Evolus
EOLS
|
100 M | $ 4.43 | -5.34 % | $ 286 M | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.37 | 0.74 % | $ 3.37 M |  Canada |
 |
Rockwell Medical
RMTI
|
74.9 M | $ 1.03 | 0.98 % | $ 24 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 6.1 | 4.1 % | $ 241 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.34 | -1.47 % | $ 402 M | Canada |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 0.9 | 2.8 % | $ 44.9 M | USA |
 |
Jupiter Wellness
JUPW
|
3.15 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
8.82 M | $ 2.34 | -8.24 % | $ 2.9 M | USA |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 2.41 | -2.43 % | $ 317 M | USA |
 |
Canopy Growth Corporation
CGC
|
189 M | $ 0.96 | -0.87 % | $ 103 M | Canada |
 |
Tilray
TLRY
|
480 M | $ 6.66 | 3.26 % | $ 4.12 B | Canada |
 |
Assertio Holdings
ASRT
|
35.4 M | $ 16.51 | 17.93 % | $ 106 M | USA |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 2.29 | -0.87 % | $ 23.9 M | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Veru
VERU
|
11 M | $ 2.29 | -0.43 % | $ 309 M | USA |
 |
Viatris
VTRS
|
8.99 B | $ 13.36 | 0.53 % | $ 16 B | USA |
 |
cbdMD
YCBD
|
7.49 M | $ 0.77 | 1.06 % | $ 3.32 M | USA |